The largest database of trusted experimental protocols

27 protocols using cleancap

1

CRISPR/BE3 Gene Editing Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Synthetic sgRNAs were manufactured by Synthego (California, US) by automated solid-phase synthesis with 2′-O-methyl 3′ phosphorothioate modifications. Single guide RNA containing a 20 nucleotide protospacer with an 80 nucleotide CRISPR scaffold were eluted in nuclease-free Tris-EDTA buffer.
sgRNA guide sequences were selected for compatibility with both SpCas9 and coBE3: TRBC 1 and 2/Exon 15′ CCCACCAGCTCAGCTCCACG 3′; CD7 Exon 25′ CACCTGCCAGGCCATCACGG 3′.
BE guides were designed to mediate cytidine to uracil to thymidine (C>U>T) modification in exon 1 of TRBC1/2 with an intended amino acid conversion of Tryptophan (Trp) to stop (STOP*) (protospacer positions G > A and/or G6 > A). CD7 exon 2-targeting sgRNA promoted the deamination-mediated conversion of Glutamine (Gln) to a premature stop (STOP*) (protospacer positions C8 > T).
CleanCap® Cas9 mRNA encoded SpCas9 was supplied by Trilink US. Custom-made codon optimised BE3 (coBE3) was supplied as CleanCap (Trilink US) with a Cap 1 structure, and polyadenylated to increase expression and stability.
+ Open protocol
+ Expand
2

Synthesis and Characterization of Modified STING mRNA

Check if the same lab product or an alternative is used in the 5 most similar protocols
Using the linearized plasmids pTEV-STINGWT-A101 and pTEV-STINGR284S-A101, the STING mRNA was produced with T7 RNA polymerase. During mRNA synthesis, 1-methylpseudouridine-5′-triphosphate (TriLink, San Diego, CA, USA) was used instead of UTP to generate modified nucleoside-containing mRNA. The STING mRNA was co-transcriptionally capped using CleanCap (TriLink) and purified as described previously [56 (link)]. The STING mRNA was analyzed by agarose gel electrophoresis and stored frozen at −80 °C.
+ Open protocol
+ Expand
3

Optimized mRNA Formulation and Purification

Check if the same lab product or an alternative is used in the 5 most similar protocols
CMmRNAs were designed with a full substitution of 1-methylpseudouridine-5′-triphosphate capped (Cap 1) and 5-methoxy-U using CleanCap™ AG, polyadenylated (120A), purified using silica membrane with DNase and phosphatase treatment, and packaged as a solution in 1mM sodium citrate, pH 6.4 (TriLink Biotechnologies).
+ Open protocol
+ Expand
4

In Vitro Synthesis of Modified mRNAs

Check if the same lab product or an alternative is used in the 5 most similar protocols
mRNAs were transcribed from linearized plasmids encoding firefly Luc, codon-optimized mEPO, EGFP, or hiNOS using T7 RNA polymerase (MEGAscript T7 Transcription Kit, Thermo Fisher Scientific, Darmstadt, Germany). The mRNAs were transcribed to contain the 5′ UTR derived from the tobacco etch virus 5′ leader RNA (TEV).34 (link) Further, a 100-nt-long poly(A) tail interrupted by a short linker (A30LA70) was transcribed from the corresponding DNA templates. For the generation of nucleoside-modified mRNAs, uridine 5’-triphosphate (UTP) was replaced with the triphosphate derivative of m1Ψ (m1ΨTP) in the transcription reaction. Capping of the IVT mRNAs was performed co-transcriptionally using the trinucleotide cap1 analog CleanCap (TriLink, San Diego, CA, USA). After DNase digestion, the synthesized mRNA was isolated from the reaction mix by precipitation with half volume of 8 M LiCl solution (Sigma-Aldrich, Hamburg, Germany), and finally the pellet was dissolved in nuclease-free water. The RNA concentration was determined using a Nanodrop 2000c spectrophotometer (Thermo Fisher Scientific). Aliquots of denatured IVT mRNAs were analyzed by electrophoresis in non-denaturing 1.4% agarose gels containing 0.005% (v/v) GelRed nucleic acid gel stain.35 (link) RiboRuler High Range RNA Ladder (Thermo Fisher Scientific) was loaded as a molecular weight marker.
+ Open protocol
+ Expand
5

Optimized mRNA Production for COVID-19 Vaccines

Check if the same lab product or an alternative is used in the 5 most similar protocols
mRNAs were transcribed from linearized plasmids encoding firefly luciferase, or full-length spike, or RBD of SARS-CoV-2 spike by the MEGAscript® T7 Transcription Kit (Cat# AMB1334-5, Life Technologies) through a modified protocol. Briefly, in order to reduce the mRNA immunity and increase its stability in vivo as COVID-19 mRNA vaccine did1 (link),2 (link), the uridine-5′-triphosphate (UTP) from the T7 Transcription Kit was replaced by m1Ψ- 5′-triphosphate (Cat# N-1081, TriLink). Meanwhile, mRNA was also capped co-transcriptionally in vitro with the trinucleotide cap1 analog CleanCap (Cat# N-7413, TriLink). After 6 h of reaction, mRNAs were precipitated by lithium chloride (LiCl) and washed twice with 75% ethanol in nuclease and endotoxin free water (Cat# W3440, Teknova). Then, the mRNA pellet was dissolved in nuclease and endotoxin free water and further subjected to cellulose purification in the presence of 16% ethanol to remove dsRNA74 (link). The concentration and purity of mRNAs was measured by nanodrop and by agarose gel electrophoresis, respectively. mRNAs were aliquoted and stored at −20 °C.
+ Open protocol
+ Expand
6

Modified RNA Synthesis Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Triphosphate-derivatives of N-methylpseudouridine (Hongene) were used to generate modified nucleoside containing RNA. All RNAs were capped using Cleancap™ (Trilink Biotechnologies). All IVT reagents except enzymes listed in (Table 1) were preheated to 37°C, mixed in a 1.5 mL plastic tube in ThermomixerTMC (Eppendorf) and incubated at 37°C with shaking at 300 rpm. The reaction was quenched after 180 min by addition of 5 mM EDTA, pH 8.0 for its subsequent purification by the different methods.
+ Open protocol
+ Expand
7

Codon-optimized mRNA Production for PR8 HA

Check if the same lab product or an alternative is used in the 5 most similar protocols
The sequence of the Puerto Rico/8/1934 influenza virus hemagglutinin (pTEV-PR8 HA-A101) was codon-optimized, synthetized and cloned to the mRNA production plasmid. The mRNA was produced using T7 RNA polymerase (Megascript, Ambion) on linearized plasmids. The mRNA was transcribed to contain 101 nucleotide-long poly(A) tails. One-methylpseudouridine (m1Ψ)-5’-triphosphate (TriLink) instead of UTP was used to generate modified nucleoside-containing mRNA. Capping of the in vitro transcribed mRNAs was performed co-transcriptionally using the trinucleotide cap1 analog, CleanCap (TriLink). mRNA was purified by cellulose purification, as described (Baiersdorfer et al., 2019 (link)). All mRNAs were analyzed by denaturing or native agarose gel electrophoresis and were stored frozen at −20°C.
+ Open protocol
+ Expand
8

Synthesis and Characterization of Modified mRNAs

Check if the same lab product or an alternative is used in the 5 most similar protocols
mRNAs were synthesized as previously described.64 (link),65 (link) Linearized plasmids encoding firefly luciferase (pTEV-Luc-A101), Cre recombinase (pTEV-Cre-A101), mouse erythropoietin (pTEV-muEPO-A51), and eGFP (pTEV-eGFP-A101) were transcribed using the MEGAscript™ T7 Transcription Kit. IVT reactions were performed in the presence of 100% modified uridines (i.e. ψUTP, m1ψUTP, or m5UTP) except for the m5C/s2U modified mRNA where 5 methylcytosine and thiouridine were added at a 1:4 mol ratio (25%) in the NTP mixture to ensure efficient transcription and subsequent translation. mRNAs were capped using either the ScriptCap™ 2′-O-Methyltransferase Kit (eGFP, muEPO) or co-transcriptionally (mLuc, Cre) using the trinucleotide cap1 analog, CleanCap (TriLink). All mRNAs were purified by cellulose purification as described.66 (link) All mRNAs were analyzed by electrophoresis using agarose gels, endotoxin tested, and dsRNA content assessed using dot blot.
+ Open protocol
+ Expand
9

Electroporation of Monocytes for Genetic Modification

Check if the same lab product or an alternative is used in the 5 most similar protocols
Monocytes were plated in RPMI, supplemented with 10% heat-inactivated FBS, and 1% P/S at 1 × 106 cells/mL in an ultra-low attachment plate for 3 h prior to transfection. Monocytes were collected and cell pellets were washed 1× PBS followed by resuspension in T buffer (Fisher Scientific, Waltham, MA, USA) at a concentration of 5 × 107 cells/mL. Cells were then loaded into a 10 uL Neon pipette tip and electroporated using a Neon Transfection System (Fisher Scientific, Waltham, MA, USA) with E5 protocol (1700 volts, 20 millisecond bandwidths, 2 pulses) unless indicated otherwise. Electroporated monocytes were then immediately transferred to 24-well plates containing 1 mL of complete monocyte medium at 5 × 105 cells/ml and placed in the tissue culture incubator.
A similar procedure was followed for experiments using chemically modified Cas9 (Cas9) mRNA instead of Cas9 RNPs. In these experiments 1 μg of sgRNA was combined with either 1.5 μg SpCas9 mRNA (CleanCap®, Trilink Biotechnologies, San Diego, CA, USA) or 1.5 μg coBE4 mRNA (Trilink Biotechnologies, San Diego, CA, USA) prior to addition to cells.
+ Open protocol
+ Expand
10

Production and Characterization of VEGF-C mRNA

Check if the same lab product or an alternative is used in the 5 most similar protocols
VEGF-C-mRNA (Extended Data Fig 2) was made by TriLink BioTechnologies (San Diego, CA), with full substitution of pseudo-uridine and 5-methyl-cytosine bases, capped using CleanCap™ AG and polyadenylated (120A). mRNA was mixed at a ratio of 1μg / 0.1μL of in vivo-jetPEI (Polyplus transfection, France) and vortexed for 30 seconds and incubated in room temperature for 15 minutes before use. Control mRNA (Cy5 labeled GFP, GFP-mRNA; Luciferase, Luc-mRNA) was also purchased from TriLink Biotechnologies. Recombinant proteins (VEGF-A, VEGF-B, VEGF-C Cys156Ser, VEGF-D) were purchased from R&D systems.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!